Ionis Pharmaceuticals, Inc. Q2 FY26 Earnings Analysis

- DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026. - Tryngolza (FCS) product sales guidance remains $100M-$110M for 2026, with strong Q1 demand suggesting growth momentum. - SHTG launch (olezarsen) planned for mid-2026 with $100M-$110M revenue estimate; broader patient access and payer coverage expected to expand in 2027, driving further growth. - Peak revenue for Tryngolza and SHTG combined projected at $3B+, up from prior $2B estimate due to updated pricing and payer research. - Collaborative revenues expected to rise, with total 2026 revenue guidance raised to $875M-$900M, including commercial and R&D milestones. - Operating expenses to increase moderately; focus on financial discipline and operating leverage improvement. - Expect cash flow breakeven by 2028 with continued investment in pipeline and launches.

- Ionis raised its 2026 total revenue guidance to $875 million to $900 million, an increase of $75 million versus prior guidance. - Commercial revenue is expected to weigh slightly more than R&D revenue within total revenue. - Product sales guidance for 2026: Tryngolza between $100 million and $110 million; DAWNZERA between $110 million and $120 million. - Operating expenses for 2026 expected to increase in the low-teen percentage range, driven primarily by sales, marketing, and launch readiness activities. - R&D expenses projected to remain steady compared to last year. - Non-GAAP operating loss forecasted between $425 million and $475 million for 2026, showing a $75 million improvement over previous guidance. - Company targets cash flow breakeven by 2028, indicating improving profitability trends beyond 2026.

- Ionis is making continued **strategic investments** to maximize the value of commercial medicines and pipeline. - Operating expenses are increasing primarily due to **commercial investments** supporting Tryngolza and DAWNZERA. - Investments also support **launch readiness activities** for olezarsen (SHTG) and zilginersen (Alexander’s disease). - Financial discipline is emphasized, with a low-teen percentage increase in operating expenses compared to last year. - Resources are being **redeployed toward late-stage pipeline drugs** fueling the next phase of growth. - Strong balance sheet (~$1.9 billion cash at Q1-end) supports continuing strategic investments. - Overall financial outlook reflects **accelerating commercial launches, advancing pipeline, and diversified revenue**, positioning for sustained growth and breakeven cash flow by 2028.

- The company ended Q1 2026 with approximately $1.9 billion in cash. - $633 million was used to repay 0% convertible notes due on April 1, 2026. - The strong balance sheet and prudent fiscal management support ongoing strategic investments. - There is no mention of any planned or upcoming fundraising through debt or equity in the current disclosures. - Focus appears to be on using existing cash and diversified revenue streams to fund operations and launches. - Cash balance is projected to remain above $1.6 billion by year-end 2026 after debt repayment. - The company aims for cash flow breakeven by 2028, implying no near-term plans for additional financing rounds have been indicated.

- Demand for Tryngolza (for FCS) is very strong, with Q1 2026 being the best quarter to date in terms of patient starts and scripts. - DAWNZERA is experiencing strong early market uptake with increasing prescriptions from both new patients and switches from existing prophylactic therapies. - For DAWNZERA in 2026, guidance is $110 million to $120 million, reflecting steady order growth driven by switches. - Olezarsen (for severe hypertriglyceridemia, SHTG) launch expected in mid-2026 with an initial revenue guidance of $100 million to $110 million, growing steadily over time as more patients are identified. - Priority review for olezarsen with a PDUFA date of June 30, 2026, supports anticipated early demand buildup. - Zilganersen (for Alexander's disease) launch planned later in 2026 focusing initially on patients from clinical trials and expanded access programs, with ongoing efforts to identify additional patients. - Overall, order momentum and patient demand are strong across multiple products heading into 2026.